Key facts
- This page summarizes Jack H. Dean's Form 4 filing for Acurx Pharmaceuticals, Inc. (ACXP).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Jan 2025, 16:30.
Jack H. Dean - 06 Jan 2025 Form 4 Insider Report for Acurx Pharmaceuticals, Inc. (ACXP)
- Reporting relationship
- Director
- Issuer ticker
- ACXP
- Reported as of
- 06 Jan 2025
- Net transaction value
- +$10,000
- SEC form
- 4
- Accepted by SEC
- 08 Jan 2025, 16:30:11 UTC
- Prior SEC filing
- 18 Jun 2024
- Next SEC filing
- 22 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kostantinos Skordalos, Power of Attorney For: Jack H. Dean
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jack H. Dean filed Form 4 for Acurx Pharmaceuticals, Inc. (ACXP) on 08 Jan 2025.
Change
- Previous filing in this sequence was filed on 18 Jun 2024.
- Current net transaction value: +$10,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACXP
transaction
Common Stock
Purchase
- Transaction value
- $10,000
- Shares
- +9,852
- Change %
- +83%
- Price
- $1.02
- Shares after
- 21,776
- Date
- 06 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
ACXP
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,770
- Date
- 06 Jan 2025
- Ownership
- By Trust
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACXP
transaction
Derivative
Warrants for Common Stock
Purchase
- Transaction value
- $0
- Shares
- +9,852
- Change %
- Price
- $0.000000
- Shares after
- 9,852
- Date
- 06 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,852
- Exercise price
- $0.9000
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc.
Footnote F2
Shares held by the Dean Family Trust. The reporting person is the Trustee of the Dean Family Trust.
Footnote F3
Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock.